PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04493619 |
|
Recruitment Status :
Terminated
(study terminated due to business realignment)
First Posted : July 30, 2020
Last Update Posted : October 5, 2022
|
Sponsor:
Opna-IO LLC
Information provided by (Responsible Party):
Opna-IO LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | April 25, 2022 |
| Actual Study Completion Date : | April 25, 2022 |